Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Market Cap:180M; Shares Outstanding:41.7M; Short Interest: 9.04%; Q3 2019(9/30/19): Cash 266M. Loss 6.09M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 261，no change
Shares hold: 45765k shares. no change
shares% hold: 109.67%，no change